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Background
Breast cancer causes the most number of deaths in
females worldwide.[1] It contributed to 14% of cancer
deaths in 2008 and is also the most commonly diag-
nosed cancer in women globally. Overexpression of the
tight junction protein junctional adhesion molecule-A
(JAM-A) in breast cancer tissue is known to produce
less favourable outcomes in breast cancer patients.
Overexpressed JAM-A may accomplish this by influen-
cing downstream signalling of key proteins involved in
cell proliferation, migration and the reaction of cells to
therapeutic agents. This study aims to further investigate
the promising role of JAM-A in breast cancer advance-
ment by assessing the consequences of changing the
structure of JAM-A on 10 key signalling proteins related
to tumour progression.
Methods
Three MDA-MB-231 cell lines were cultured. Two of
the cell lines overexpressed JAM-A mutants, one with
the first IgG loop deleted (DL1) and another with muta-
tions at E61A and K63A (6163). The third was an
empty vector cell line with normal levels of non-
mutated JAM-A (EV). Preliminary Western blotting stu-
dies were used to screen cell lines for 10 key signalling
proteins associated with tumour aggressiveness. The
optical density for each band formed on film were ana-
lysed using ImageJ software. For each signalling protein,
the density reading for each overexpressed cell line was
compared against the EV cell line that was given a base
value of ‘1’.
Results
Overexpression of mutant JAM-A (DL1) resulted in
increased levels of PAR6, p38, phospho-p38, aPKC, b1
integrin, pERK, pAKT and PAR3 signalling proteins. PTEN
and ERK levels were essentially unchanged. Overexpression
of mutant JAM-A (6163) resulted in increased levels of
p38, phospho-p38 and pERK; while PAR6, aPKC, b1 integ-
rin, ERK, pAKT and PAR3 all showed decreased levels.
Conclusions
Our data in breast cells show that mutation of JAM-A can
alter the levels of 10 key signalling proteins. In various
studies conducted, increased levels of Par6, p38, phospho-
P38, aPKC, beta1 integrin, ERK, pERK and pAkt may facil-
itate tumourigenicity, while decreased levels of PAR3 and
PTEN in cells may do likewise. Thus the changes in sig-
nalling protein levels acquired from our data suggest that
mutant JAM-A (DL1) assists the development of malig-
nancy in breast cancer cells, however mutant JAM-A
(6163) may not have the same effect. There is currently a
scarce pool of knowledge on the role of JAM-A in breast
cancer advancement and our study provides a rationale for
further investigation into this relationship.
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